Phathom Pharmaceuticals, Inc.

NasdaqGS PHAT

Phathom Pharmaceuticals, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2024: USD 22.34 M

Phathom Pharmaceuticals, Inc. Gross Profit is USD 22.34 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 4,102.69% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Phathom Pharmaceuticals, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -558.00 K, a 4.94% change year over year.
Phathom Pharmaceuticals, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -587.00 K, a -52.07% change year over year.
Phathom Pharmaceuticals, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -386.00 K, a 0.00% change year over year.
Phathom Pharmaceuticals, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 0.00, a 0.00% change year over year.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

NasdaqGS: PHAT

Phathom Pharmaceuticals, Inc.

CEO	Ms. Terrie J. Curran
IPO Date	Oct. 25, 2019
Location	United States
Headquarters	100 Campus Drive
Employees	452
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Key trends

Past 5 years